Evidence map›Paper›PMID 42209908›Full record

ArticleInternational urology and nephrology2026

Initial clinical experience with RADA16 as a novel therapeutic for severe haemorrhagic radiation cystitis: a preliminary feasibility case series.

Petre Cristian Ilie, Anne Carrie, Yacine Touati, Robert Mills, Croitoru Radu, Claudiu Tanase, Ruth Doherty, Will Finch, David Manson-Bahr, Fiona Richardson and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Petre Cristian IlieUrology Department, The Queen Elizabeth Hospital Foundation Trust, King's Lynn, UK. petre.ilie@nnuh.nhs.uk.
Anne CarrieUrology Department, Norfolk and Norwich University Hospital, Norwich, UK.
Yacine TouatiUrology Department, The Queen Elizabeth Hospital Foundation Trust, King's Lynn, UK.
Robert MillsUrology Department, Norfolk and Norwich University Hospital, Norwich, UK.
Croitoru RaduUrology Department, The Queen Elizabeth Hospital Foundation Trust, King's Lynn, UK.
Claudiu TanaseUrology Department, The Queen Elizabeth Hospital Foundation Trust, King's Lynn, UK.
Ruth DohertyUrology Department, Norfolk and Norwich University Hospital, Norwich, UK.
Will FinchUrology Department, Norfolk and Norwich University Hospital, Norwich, UK.
David Manson-BahrUrology Department, Norfolk and Norwich University Hospital, Norwich, UK.
Fiona RichardsonResearch and Innovation Department, The Queen Elizabeth Hospital Foundation Trust, King's Lynn, UK.
Tom DymondResearch and Innovation Department, The Queen Elizabeth Hospital Foundation Trust, King's Lynn, UK.
Lee SmithCentre for Health Performance and Wellbeing, Anglia Ruskin University, Cambridge, CB1 1PT, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHaemorrhagic radiation cystitis (HRC) is a challenging complication of pelvic radiotherapy, often resistant to conventional treatments.

aimsTo evaluate the clinical efficacy and safety of RADA16, a self-assembling peptide, in managing severe HRC.

methodsA preliminary feasibility case series of five consecutive patients treated at two UK hospitals. All patients had persistent haematuria despite standard interventions and received RADA16 via flexible or rigid cystoscopy.

resultsThe findings from the cases suggest that all patients have experienced at least a partial or early resolution of haematuria and no adverse effects were reported. In most cases, two applications of RADA16 were sufficient. The longest patient followed up was still symptom free at 3 years. DISCUSSION: This preliminary feasibility case series has demonstrated early efficacy for RADA16 in the management of HRC.

conclusionsRADA16 is a potentially promising minimally invasive treatment for refractory HRC. Further trials are warranted to confirm these findings.

Indexed as

HaematuriaHaemorrhagic cystitisPuraBondPuraStatRADA16Radiation cystitis

Identifiers

PMID42209908

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.